High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q2
FY2026Q3
4.26M
+19.03%
-0.310
-47.46%
5.47M
+53.59%
-0.290
-53.97%
Estimates Revision
The market is revising No Change the revenue expectations for Sonoma Pharmaceuticals, Inc. (SNOA) for FY2026, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -24.52%.
Revenue Estimates for FY2026
No Change
0.00%
In Past 3 Month
EPS Estimates for FY2026
No Change
0.00%
In Past 3 Month
Stock Price
Go Down
-24.52%
In Past 3 Month
Valuation Metrics
The current forward P/E ratio for Sonoma Pharmaceuticals Inc (SNOA.O) is -3.84, compared to its 5-year average forward P/E of -1.11. For a more detailed relative valuation and DCF analysis to assess Sonoma Pharmaceuticals Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-1.11
Current PE
-3.84
Overvalued PE
0.17
Undervalued PE
-2.38
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.40
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.19
Undervalued EV/EBITDA
-0.40
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
0.28
Current PS
0.00
Overvalued PS
0.40
Undervalued PS
0.16
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
SNOA News & Events
Events Timeline
(ET)
2025-11-13
08:49:28
Sonoma Pharmaceuticals' Reliefacyn Advanced Earns NRS Seal of Acceptance
2025-11-04 (ET)
2025-11-04
08:57:47
Sonoma Pharmaceuticals announces Q2 earnings per share of 32 cents, compared to a loss of 59 cents in the same period last year.
2025-10-14 (ET)
2025-10-14
08:39:33
Sonoma Pharmaceuticals and Medline Introduce HOCI Wound Cleansing Solution
Sign Up For More Events
Sign Up For More Events
News
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/579c99e9a98a7638cf2d4c9a68ffd77550f9c0c1bfc21450f5b4ba753237f29c.png)
Preview
2.0
08-21Benzinga5 Healthcare Stocks Soaring This Week
![[object Object]](https://www.nasdaq.com/sites/acquia.prod/files/rttnews_article/chartsignals-15082025-m.jpg)
Preview
2.0
08-15NASDAQ.COMStocks Moving Premarket: PMNT, KULR, ENLV, ORGN, And Other Gainers & Losers
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/default_image/tipranks.png)
Preview
4.5
08-15TipRanksMorning News Wrap-Up: Thursday’s Biggest Stock Market Stories!
Sign Up For More News
People Also Watch
FAQ
What is Sonoma Pharmaceuticals Inc (SNOA) stock price today?
What is Sonoma Pharmaceuticals Inc (SNOA)'s business?
What is the price predicton of SNOA Stock?
What is Sonoma Pharmaceuticals Inc (SNOA)'s revenue for the last quarter?
What is Sonoma Pharmaceuticals Inc (SNOA)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Sonoma Pharmaceuticals Inc (SNOA)'s fundamentals?
How many employees does Sonoma Pharmaceuticals Inc (SNOA). have?